97 related articles for article (PubMed ID: 1525061)
1. The antitumor potency of progesterone antagonists is due to their differentiation potential.
Michna H; Gehring S; Kühnel W; Nishino Y; Schneider MR
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):203-10. PubMed ID: 1525061
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat.
Schneider MR; Michna H; Nishino Y; el Etreby MF
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):691-701. PubMed ID: 2497018
[TBL] [Abstract][Full Text] [Related]
3. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death.
Michna H; Schneider MR; Nishino Y; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):447-53. PubMed ID: 2626038
[TBL] [Abstract][Full Text] [Related]
4. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.
Michna H; Schneider MR; Nishino Y; el Etreby MF
Breast Cancer Res Treat; 1989 Dec; 14(3):275-88. PubMed ID: 2514814
[TBL] [Abstract][Full Text] [Related]
6. Progesterone antagonists: tumor-inhibiting potential and mechanism of action.
Michna H; Nishino Y; Neef G; McGuire WL; Schneider MR
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):339-48. PubMed ID: 1562510
[TBL] [Abstract][Full Text] [Related]
7. The tumour-inhibiting potential of the progesterone antagonist Onapristone in the human mammary carcinoma T61 in nude mice.
Schneider MR; Michna H; Habenicht UF; Nishino Y; Grill HJ; Pollow K
J Cancer Res Clin Oncol; 1992; 118(3):187-9. PubMed ID: 1548283
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models.
Schneider MR; Michna H; Nishino Y; el Etreby MF
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):783-7. PubMed ID: 2285591
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of the antitumor efficacy of the antiprogestin, onapristone, by combination with the antiestrogen, ICI 164384.
Nishino Y; Schneider MR; Michna H
J Cancer Res Clin Oncol; 1994; 120(5):298-302. PubMed ID: 8126059
[TBL] [Abstract][Full Text] [Related]
10. A bioassay for the evaluation of antiproliferative potencies of progesterone antagonists.
Michna H; Nishino Y; Schneider MR; Louton T; el Etreby MF
J Steroid Biochem Mol Biol; 1991 Mar; 38(3):359-65. PubMed ID: 1706934
[TBL] [Abstract][Full Text] [Related]
11. Progesterone antagonists block the growth of experimental mammary tumors in G0/G1.
Michna H; Schneider M; Nishino Y; el Etreby MF; McGuire WL
Breast Cancer Res Treat; 1990 Dec; 17(2):155-6. PubMed ID: 2096993
[No Abstract] [Full Text] [Related]
12. Natural and synthetic progestins accelerate 7,12-dimethylbenz[a]anthracene-initiated mammary tumors and increase angiogenesis in Sprague-Dawley rats.
Benakanakere I; Besch-Williford C; Schnell J; Brandt S; Ellersieck MR; Molinolo A; Hyder SM
Clin Cancer Res; 2006 Jul; 12(13):4062-71. PubMed ID: 16818706
[TBL] [Abstract][Full Text] [Related]
13. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.
Chwalisz K; Stöckemann K; Fritzemeier KH; Fuhrmann U
Hum Reprod Update; 1998; 4(5):570-83. PubMed ID: 10027611
[TBL] [Abstract][Full Text] [Related]
14. Morphology of the rat uterus after long-term treatment with progesterone antagonists.
Rumpel E; Michna H; Kühnel W
Ann Anat; 1993 Apr; 175(2):141-9. PubMed ID: 8489034
[TBL] [Abstract][Full Text] [Related]
15. Potent inhibitory effect of a new antiestrogen (RU 16117) on the growth of 7,12-dimethylbenz[a]anthracene-induced rat mammary tumors.
Kelly PA; Asselin J; Caron MG; Labrie F; Raynaud JP
J Natl Cancer Inst; 1977 Mar; 58(3):623-8. PubMed ID: 402479
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in MNU and DMBA-induced mammary tumors in female rats.
Alvarado A; Lopes AC; Faustino-Rocha AI; Cabrita AMS; Ferreira R; Oliveira PA; Colaço B
Pathol Res Pract; 2017 May; 213(5):441-446. PubMed ID: 28285967
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo.
Matsuda Y; Kawamoto K; Kiya K; Kurisu K; Sugiyama K; Uozumi T
J Neurosurg; 1994 Mar; 80(3):527-34. PubMed ID: 8113866
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of tenascin expression by antiprogestins during terminal differentiation of rat mammary tumors.
Vollmer G; Michna H; Ebert K; Knuppen R
Cancer Res; 1992 Sep; 52(17):4642-8. PubMed ID: 1380887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]